

All about skin and hair bioscience!

State-of-the-art technology and expertise for all your pre-clinical, mechanistic, and clinical needs in dermatology research.

- Pre-clinical Research
- Clinical Research
- Education

Psoriasis


Psoriasis



Lesional skin



Peri-lesional skin



"We combine our unique expertise, our project design creativity, and our passion to advance our clients' success in delivering novel and gamechanging skin and hair research solutions"

> President: Prof. Dr. Ralf Paus

Download flyer



Monasterium Laboratory

Skin & Hair Research Solutions GmbH

Mendelstr. 17, 48149 Münster, Germany Phone: +49 (0) 251 93264-458 Fax: +49 (0) 251 93264-457

www.monasteriumlab.com

Dr. Marta Bertolini (PhD)


CEO:

For inquiries, please contact:


m.bertolini@monasteriumlab.com + 49 (0)251 93263-080

Modeling psoriasis-like responses in primary epidermal keratinocytes *in vitro*


Cytokine cocktail (IL-17A/TNFα) successfully induces psoriasis-associated gene expression in human epidermal keratinocytes



Study Example: Secukinumab inhibits transcriptional changes and reduces the release of β2– defensin (BD2) and CCL20 into the medium induced by IL–17A+TNFα




Isolation of psoriasis-relevant immune cells from healthy and psoriatic human blood and skin




FACS plots generated from healthy human blood. We can detect B-cells (CD19+), monocytes (CD14+), CD4+ or CD8+ T-cells, but also neutrophils (CD56+), dendritic cells (CD11c+), mast cells (CD117+), and more. In further steps, the CD4+ T-cell population can be analyzed for psoriasis-relevant immune cell subtypes e.g. skin migrating T cells (CLA+, CD4+), and Th1 (CXCR3+CCR4-CCR6-), Th17 (CXCR3-CCR4+CCR6+CCR10-), Th1+17 (CXCR3+CCR4-CCR6+) or Th22 (CXCR3+CCR4+CCR6+CCR10+) polarized CD4+ T-cells.

Identification of psoriasis-relevant cytokines from psoriatic human blood



Modeling psoriasis-like responses in human HEALTHY skin ex vivo


Cytokine cocktail activates epidermal keratinocytes and resident immune cells inducing a psoriasis-like phenotype




Resident skin immune cells still present and stimulated by cytokine cocktail!


CD3 expression in the skin

K15 expression in the basal layer






TNFa treatment of human healthy skin stimulates the secretion of psoriasis relevant cytokines into the medium




Investigating the effect of a drug on lesional skin from psoriasis patients *ex vivo*


Psoriasis phenotype of patient skin is maintained during ex vivo organ culture



Study Example: Secukinumab (Sec) ameliorates psoriasis disease phenotype *ex vivo*, i.e. reduces the transcriptome differences between lesional and peri-lesional skin




Number of differentially expressed genes




Target characterization or identification

Analysis of human psoriasis patient skin biopsies



Investigating the effect of a drug on inhibiting psoriasis-like phenotype *in vivo*: Humanized mouse model



CD11c+ dendritic cells


Alternative, *allogeneic IL-2 stimulated PBMCs from psoriasis patients* can be also used to induce psoriasis phenotype.

Keren et al., J Allergy Clin Immunol. 2018; Gilhar et al., J Invest Dermatol. 2011; Schafer et al., Br J Pharmacol. 2010 Custom-choice drug treatment by delivery through

- 1. Systemic treatment
- 2. Topical treatment


can be applied **prophylactically** or **therapeutically** to prevent or reverse the psoriasiform phenotype. Endpoint analysis of xenograft and terminal blood can be customized including classical quantitative Immunohistomorphometry, RNAseq, and cytokine assay.

Psoriasiform




Investigating the effect of a drug on inhibiting a psoriasis-like phenotype *in vivo*: Humanized mouse model

Psoriasis-like response in the skin



Amelioration of disease after treatment with dexamethasone



WHY US?

Great network of dermatologists and plastic surgeons collecting <u>samples</u> <u>from healthy and</u> <u>diseased skin</u> Our vision is to provide our clients and partners with the highest quality research in investigative dermatology and trichology – from basic science to translational applied and contract research of high relevance for clinical applications.



Clinically-

relevant

ex vivo and in

vivo models

World-class scientific leadership & international team

Strong academic background & publication record

Our ambition is to

establish and refine research techniques:

Advanced Methodology

Program

What we can do for our clients:

- Conceptualize & build proof-of-concept studies
- Carry out full service portfolio for pre-clinical skin & hair research (*in vitro*/*ex vivo* assays, and humanized mouse models)
- Investigate side effects in the skin or hair follicle
- Establish novel cutting edge methodologies and techniques
- Design tailor-made & customized assays for all needs
- Identify, characterize, or validate novel targets and therapeutics for skin & hair disorders
- Discover mechanistic action stories, biomarkers & predictors of response
- Conduct investigator initiated skin & hair clinical trials
- Provide access to human healthy & diseased skin and hair specimen
- Prepare comprehensive project reports & manuscript drafts

Investigative dermatology: **Biobank:** Acne Vulgaris, Atopic We are supported Full access to skin Dermatitis, Psoriasis, by world-wide & hair samples Alopecia Areata, recognized (patients & Androgenic Alopecia, experts in Exceptional healthy subjects) Hidradenitis Suppurativa, dermatology state-of-the-art Vitiligo, Chronic Itch, research Prurigo Nodularis, technology etc.

Monasterium Laboratory Skin & Hair Research Solutions GmbH was founded in 2015 by Prof. Ralf Paus, MD, FRSB.

Global client list & testimonials